Molecular Diagnostics

Cypress, CA, United States

Molecular Diagnostics

Cypress, CA, United States

Time filter

Source Type

News Article | May 17, 2017
Site: www.businesswire.com

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Transplant Matching Molecular Diagnostics Market" report to their offering. Molecular HLA typing methods allow more precise matching between donor and recipient and is especially critical to bone marrow or HSCT transplant outcomes. Allogenic HSCT transplantation is a relatively high growth procedure area compared to solid organ transplantation and is a leading area of application for molecular HLA typing. Polymorphism in the human major histocompability complex (MHC) or HLA system is exceedingly complex for serological methods and is best captured by directly assaying genetic sequence. The molecular HLA typing market is provided for various regions, and forecasts are made to 2021. In addition the report discusses trends affecting the molecular transplant matching market. Successful solid organ and hematopoietic stem cell (HSCT) or bone marrow transplants require histocompatibility between the recipient and donor. Autologous transplantation using hematopoietic cells from the same patient (donor and recipient) is increasingly common and eliminates the need to screen for histocompatibility. However, solid organ transplants and HSCT allografts from another donor requires histocompatibility confirmed by human leukocyte antigen (HLA) testing outside of genetically identical twins. Proteins encoded by HLA system genes function as unique cell surface markers that regulate immune system recognition of foreign cells such as pathogens and tumor cells. Incompatibility between donor and recipient HLA systems or between donor tissue and recipient antibodies can result in severe complications such as transplant rejection. Testing of donor and recipient HLA systems is essential in cases of allograft between unrelated and even siblings. The most common forms of HLA typing are serological testing of HLA antigens and antibodies and detection of HLA alleles using a variety of molecular diagnostic techniques. Next-generation sequencing (NGS) is expected to develop into a leading option for the determination of HLA alleles. For more information about this report visit http://www.researchandmarkets.com/research/3tp5t8/transplant


News Article | May 16, 2017
Site: globenewswire.com

DELRAY BEACH, Fla., May 16, 2017 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTC:PSID), a Life Sciences company focused on detection and diagnostics, announced today its financial results for the quarter ended March 31, 2017. The Company's Form 10-Q can be found in the Investor Relations section of its website. For the quarter ended March 31, 2017, revenues were $1.2 million, compared to $1.0 million for the prior sequential quarter, and $1.7 million for the quarter ended March 31, 2016. The decreased revenue from the first quarter of 2017 compared to the prior year quarter was driven by the delivery of two large projects in the Company’s Mobile Labs segment in early 2016. In early 2017 work progressed on several mobile labs, which will likely not be delivered until the second half of 2017. As individual projects are usually material, revenues can vary materially period to period based on the timing of such deliveries, and quarterly revenue as a result may not reflect results projected over an annual period. Cost of revenue was $0.8 million for the quarter ended March 31, 2017, compared to $0.7 million for the prior sequential quarter, and $1.1 million for quarter ended March 31, 2016. Gross margins increased to 34% for quarter ended March 31, 2017, compared to 32% for the prior sequential quarter and the quarter ended March 31, 2016. The decreased cost of revenue was primarily driven by the decrease in sales, while the improved margin resulted from improved mix of business. “During the first quarter of 2017, our businesses performed solidly, reporting an increase in revenue of 25% over the prior sequential quarter, with a focus on building a strong pipeline for the remainder of 2017,” stated William J. Caragol, Chairman and CEO of PositiveID. “While the timing of delivery of vehicles in our Mobile Labs segment can affect results from one quarter to another, we are confident in our business pipeline for the second half of the year, and looking at the big picture, we expect 2017 revenues will exceed 2016 revenues of $5.6 million.” PositiveID operates in three segments: Mobile Labs, comprised of its E-N-G Mobile Systems (“ENG”) subsidiary; Medical Devices, comprised of its Thermomedics subsidiary; and Molecular Diagnostics, consisting of its Firefly Dx prototype system for real-time pathogen detection. ENG designs and builds mobile laboratories, wireless support vehicles (cell-on-wheels and cell-on-light-trucks), radio frequency (“RF”) test platforms, broadcast news vehicles, and other technical vehicles. ​ENG has delivered more than 1,500 specialty vehicles to customers around the globe, including more than 400 mobile laboratories, 600 broadcast news vehicles, and more than 400 vehicles for cellular, RF, infrared, and other applications. Thermomedics markets the FDA-cleared Caregiver® thermometer, which is a clinical grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants, without contact. It delivers an oral-equivalent temperature directly from the forehead in one to two seconds. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs. PositiveID is developing the Firefly Dx prototype system to be a handheld, fully automated, lab quality, real-time device able to detect pathogens at the point of need, faster and less expensively than existing devices. Firefly's applications include point-of-need, lab-quality, detection of pathogenic organisms; agricultural and food screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction. About PositiveID Corporation PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn. Statements about PositiveID's future expectations, including the likelihood that several mobile labs will likely not be delivered until the second half of 2017; the likelihood that quarterly revenue may not reflect results projected over an annual period; the likelihood that the Company expects 2017 revenues will exceed 2016 revenues of $5.6 million; the likelihood that Firefly's applications include point-of-need, lab-quality, detection of pathogenic organisms, agricultural and food screening in both domestic sectors and developing countries, and detection of biological agents associated with weapons of mass destruction; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the specialty vehicle market; the Company’s ability to attract new customers and retain existing customers; the Company’s ability to target the professional healthcare market; the Company’s ability to raise capital; the Company’s ability complete the testing and development of Firefly Dx; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 31, 2017, and 10-Qs filed on May 15, 2017, November 18, 2016, and August 12, 2016, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.


Receive press releases from iHealthcareAnalyst, Inc.: By Email Global Clinical Diagnostics Market Research Reports, Competitive Analytics, Trends and Forecast 2017-2021 by iHealthcareAnalyst, Inc. Clinical Diagnostics Market reports by iHealthcareAnalyst, Inc. include Autoimmune Disease Diagnostics, Cancer Diagnostics, Cervical Cancer Diagnostic Testing, Cervical Cancer Diagnostics, Cervical Dysplasia Diagnostics, Circulating Tumor Cells Prognostic Technologies, Companion Diagnostic Testing, Dermatology Diagnostics and Therapeutics, Enteric Disease Testing, Forensic Technologies, Hepatitis E Diagnostics, Hospital Acquired Disease Testing, Lateral Flow Disease Testing, etc. Maryland Heights, MO, May 19, 2017 --( The global clinical diagnostics market report provides market size (Revenue USD Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021). The global market research reports are divided by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global reports also provide detailed market landscape (market drivers, restraints, opportunities), market attractiveness and profitability analysis as well as profiles of major competitors in the global market which includes company overview, financial snapshot, key products, technologies and services offered, and recent developments. Browse Global Clinical Diagnostics Reports, Competitive Analytics, Growth Trends and Forecast 2017-2021 by iHealthcareAnalyst, Inc. at https://www.ihealthcareanalyst.com/reports/clinical-diagnostics/ Table of Contents 1. Introduction 2. Executive Summary 2.1. Market Size Estimation (Revenue USD Million, 2014-2021) 2.2. Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021) 3. Research Methodology 4. Market Landscape 4.1. Market Dynamics 4.1.1. Drivers 4.1.2. Barriers 4.1.3. Opportunities 4.2. Market Share Analysis 4.2.1. Companies 4.2.2. Products 4.3. Market Trends Analysis 4.3.1. Key success factors 4.3.2. Market Growth Rate 4.4. Market Attractiveness Analysis 4.5. Market Profitability Analysis 4.5.1. Buyer power 4.5.2. Supplier power 4.5.3. Barriers to entry 4.5.4. Threat of substitute products 4.5.5. Rivalry among firms in the industry 4.6. Distribution Channels 5. Market Segmentation 5.1. Diagnostic Test Type 5.2. Indication or Infection Type 5.3. Technology 5.4. Diagnostics Application 5.5. Service Type 5.6. End User Groups 6. Geography (Region, Country) 6.1. North America (U.S., Canada) 6.2. Latin America (Brazil, Mexico, Rest of LA) 6.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU) 6.4. Asia Pacific (Japan, China, India, Rest of APAC) 6.5. Rest of the World 7. Regulatory Overview 7.1. Device Classification I, II, III, IV 7.2. Device (FDA, EMEA) Approvals 8. Company Profiles 8.1. Company Overview 8.2. Financial Snapshot (FY 2014-2016) 8.3. Product Portfolio 8.4. Business Strategies 8.5. Recent Developments 9. Recommendations 10. References To request Table of Contents and Sample Pages of these reports visit: https://www.ihealthcareanalyst.com/reports/clinical-diagnostics/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, May 19, 2017 --( PR.com )-- The published titles of Clinical Diagnostics Market reports by iHealthcareAnalyst, Inc. include Autoimmune Disease Diagnostics, Cancer Diagnostics, Cervical Cancer Diagnostic Testing, Cervical Cancer Diagnostics, Cervical Dysplasia Diagnostics, Circulating Tumor Cells Prognostic Technologies, Companion Diagnostic Testing, Dermatology Diagnostics and Therapeutics, Enteric Disease Testing, Forensic Technologies, Hepatitis E Diagnostics, Hospital Acquired Disease Testing, Lateral Flow Disease Testing, Multiplex Molecular Diagnostics, Noninvasive Prenatal Testing, Preimplantation Genetic Diagnosis Testing - Diagnostic Test Types (Aneuploidy Screening, Chromosomal Aberrations, Gender Selection, HLA Typing, Single Gene Disorders, X-Linked Diseases) and Forecast 2017-2021 Rapid Medical Diagnostic Kits, Respiratory Disease Testing, Sexually Transmitted Diseases Diagnostics, Tissue Diagnostics, Tuberculosis Diagnostics, and Scleroderma Diagnostics and Therapeutics.The global clinical diagnostics market report provides market size (Revenue USD Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021). The global market research reports are divided by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global reports also provide detailed market landscape (market drivers, restraints, opportunities), market attractiveness and profitability analysis as well as profiles of major competitors in the global market which includes company overview, financial snapshot, key products, technologies and services offered, and recent developments.Browse Global Clinical Diagnostics Reports, Competitive Analytics, Growth Trends and Forecast 2017-2021 by iHealthcareAnalyst, Inc. at https://www.ihealthcareanalyst.com/reports/clinical-diagnostics/Table of Contents1. Introduction2. Executive Summary2.1. Market Size Estimation (Revenue USD Million, 2014-2021)2.2. Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)3. Research Methodology4. Market Landscape4.1. Market Dynamics4.1.1. Drivers4.1.2. Barriers4.1.3. Opportunities4.2. Market Share Analysis4.2.1. Companies4.2.2. Products4.3. Market Trends Analysis4.3.1. Key success factors4.3.2. Market Growth Rate4.4. Market Attractiveness Analysis4.5. Market Profitability Analysis4.5.1. Buyer power4.5.2. Supplier power4.5.3. Barriers to entry4.5.4. Threat of substitute products4.5.5. Rivalry among firms in the industry4.6. Distribution Channels5. Market Segmentation5.1. Diagnostic Test Type5.2. Indication or Infection Type5.3. Technology5.4. Diagnostics Application5.5. Service Type5.6. End User Groups6. Geography (Region, Country)6.1. North America (U.S., Canada)6.2. Latin America (Brazil, Mexico, Rest of LA)6.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)6.4. Asia Pacific (Japan, China, India, Rest of APAC)6.5. Rest of the World7. Regulatory Overview7.1. Device Classification I, II, III, IV7.2. Device (FDA, EMEA) Approvals8. Company Profiles8.1. Company Overview8.2. Financial Snapshot (FY 2014-2016)8.3. Product Portfolio8.4. Business Strategies8.5. Recent Developments9. Recommendations10. ReferencesTo request Table of Contents and Sample Pages of these reports visit:https://www.ihealthcareanalyst.com/reports/clinical-diagnostics/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc.


News Article | May 16, 2017
Site: globenewswire.com

DELRAY BEACH, Fla., May 16, 2017 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTC:PSID), a Life Sciences company focused on detection and diagnostics, announced today its financial results for the quarter ended March 31, 2017. The Company's Form 10-Q can be found in the Investor Relations section of its website. For the quarter ended March 31, 2017, revenues were $1.2 million, compared to $1.0 million for the prior sequential quarter, and $1.7 million for the quarter ended March 31, 2016. The decreased revenue from the first quarter of 2017 compared to the prior year quarter was driven by the delivery of two large projects in the Company’s Mobile Labs segment in early 2016. In early 2017 work progressed on several mobile labs, which will likely not be delivered until the second half of 2017. As individual projects are usually material, revenues can vary materially period to period based on the timing of such deliveries, and quarterly revenue as a result may not reflect results projected over an annual period. Cost of revenue was $0.8 million for the quarter ended March 31, 2017, compared to $0.7 million for the prior sequential quarter, and $1.1 million for quarter ended March 31, 2016. Gross margins increased to 34% for quarter ended March 31, 2017, compared to 32% for the prior sequential quarter and the quarter ended March 31, 2016. The decreased cost of revenue was primarily driven by the decrease in sales, while the improved margin resulted from improved mix of business. “During the first quarter of 2017, our businesses performed solidly, reporting an increase in revenue of 25% over the prior sequential quarter, with a focus on building a strong pipeline for the remainder of 2017,” stated William J. Caragol, Chairman and CEO of PositiveID. “While the timing of delivery of vehicles in our Mobile Labs segment can affect results from one quarter to another, we are confident in our business pipeline for the second half of the year, and looking at the big picture, we expect 2017 revenues will exceed 2016 revenues of $5.6 million.” PositiveID operates in three segments: Mobile Labs, comprised of its E-N-G Mobile Systems (“ENG”) subsidiary; Medical Devices, comprised of its Thermomedics subsidiary; and Molecular Diagnostics, consisting of its Firefly Dx prototype system for real-time pathogen detection. ENG designs and builds mobile laboratories, wireless support vehicles (cell-on-wheels and cell-on-light-trucks), radio frequency (“RF”) test platforms, broadcast news vehicles, and other technical vehicles. ​ENG has delivered more than 1,500 specialty vehicles to customers around the globe, including more than 400 mobile laboratories, 600 broadcast news vehicles, and more than 400 vehicles for cellular, RF, infrared, and other applications. Thermomedics markets the FDA-cleared Caregiver® thermometer, which is a clinical grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants, without contact. It delivers an oral-equivalent temperature directly from the forehead in one to two seconds. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs. PositiveID is developing the Firefly Dx prototype system to be a handheld, fully automated, lab quality, real-time device able to detect pathogens at the point of need, faster and less expensively than existing devices. Firefly's applications include point-of-need, lab-quality, detection of pathogenic organisms; agricultural and food screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction. About PositiveID Corporation PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn. Statements about PositiveID's future expectations, including the likelihood that several mobile labs will likely not be delivered until the second half of 2017; the likelihood that quarterly revenue may not reflect results projected over an annual period; the likelihood that the Company expects 2017 revenues will exceed 2016 revenues of $5.6 million; the likelihood that Firefly's applications include point-of-need, lab-quality, detection of pathogenic organisms, agricultural and food screening in both domestic sectors and developing countries, and detection of biological agents associated with weapons of mass destruction; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the specialty vehicle market; the Company’s ability to attract new customers and retain existing customers; the Company’s ability to target the professional healthcare market; the Company’s ability to raise capital; the Company’s ability complete the testing and development of Firefly Dx; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 31, 2017, and 10-Qs filed on May 15, 2017, November 18, 2016, and August 12, 2016, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.


News Article | May 16, 2017
Site: globenewswire.com

DELRAY BEACH, Fla., May 16, 2017 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTC:PSID), a Life Sciences company focused on detection and diagnostics, announced today its financial results for the quarter ended March 31, 2017. The Company's Form 10-Q can be found in the Investor Relations section of its website. For the quarter ended March 31, 2017, revenues were $1.2 million, compared to $1.0 million for the prior sequential quarter, and $1.7 million for the quarter ended March 31, 2016. The decreased revenue from the first quarter of 2017 compared to the prior year quarter was driven by the delivery of two large projects in the Company’s Mobile Labs segment in early 2016. In early 2017 work progressed on several mobile labs, which will likely not be delivered until the second half of 2017. As individual projects are usually material, revenues can vary materially period to period based on the timing of such deliveries, and quarterly revenue as a result may not reflect results projected over an annual period. Cost of revenue was $0.8 million for the quarter ended March 31, 2017, compared to $0.7 million for the prior sequential quarter, and $1.1 million for quarter ended March 31, 2016. Gross margins increased to 34% for quarter ended March 31, 2017, compared to 32% for the prior sequential quarter and the quarter ended March 31, 2016. The decreased cost of revenue was primarily driven by the decrease in sales, while the improved margin resulted from improved mix of business. “During the first quarter of 2017, our businesses performed solidly, reporting an increase in revenue of 25% over the prior sequential quarter, with a focus on building a strong pipeline for the remainder of 2017,” stated William J. Caragol, Chairman and CEO of PositiveID. “While the timing of delivery of vehicles in our Mobile Labs segment can affect results from one quarter to another, we are confident in our business pipeline for the second half of the year, and looking at the big picture, we expect 2017 revenues will exceed 2016 revenues of $5.6 million.” PositiveID operates in three segments: Mobile Labs, comprised of its E-N-G Mobile Systems (“ENG”) subsidiary; Medical Devices, comprised of its Thermomedics subsidiary; and Molecular Diagnostics, consisting of its Firefly Dx prototype system for real-time pathogen detection. ENG designs and builds mobile laboratories, wireless support vehicles (cell-on-wheels and cell-on-light-trucks), radio frequency (“RF”) test platforms, broadcast news vehicles, and other technical vehicles. ​ENG has delivered more than 1,500 specialty vehicles to customers around the globe, including more than 400 mobile laboratories, 600 broadcast news vehicles, and more than 400 vehicles for cellular, RF, infrared, and other applications. Thermomedics markets the FDA-cleared Caregiver® thermometer, which is a clinical grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants, without contact. It delivers an oral-equivalent temperature directly from the forehead in one to two seconds. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs. PositiveID is developing the Firefly Dx prototype system to be a handheld, fully automated, lab quality, real-time device able to detect pathogens at the point of need, faster and less expensively than existing devices. Firefly's applications include point-of-need, lab-quality, detection of pathogenic organisms; agricultural and food screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction. About PositiveID Corporation PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn. Statements about PositiveID's future expectations, including the likelihood that several mobile labs will likely not be delivered until the second half of 2017; the likelihood that quarterly revenue may not reflect results projected over an annual period; the likelihood that the Company expects 2017 revenues will exceed 2016 revenues of $5.6 million; the likelihood that Firefly's applications include point-of-need, lab-quality, detection of pathogenic organisms, agricultural and food screening in both domestic sectors and developing countries, and detection of biological agents associated with weapons of mass destruction; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the specialty vehicle market; the Company’s ability to attract new customers and retain existing customers; the Company’s ability to target the professional healthcare market; the Company’s ability to raise capital; the Company’s ability complete the testing and development of Firefly Dx; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 31, 2017, and 10-Qs filed on May 15, 2017, November 18, 2016, and August 12, 2016, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Infectious Disease Molecular Diagnostics Market (Hepatitis, HIV/CT/NG/HPV and Other Tests)" report to their offering. Growth is expected to be higher than the overall molecular testing market for the next five years. This is according to Kalorama Information's latest study on the molecular microbiology/virology markets. This category is projected to account for 60% of the global molecular diagnostics market by 2021. The market segment is defined by test decentralization with the introduction of NAAT platforms able to be operated in hospital labs and near-patient points of care such as physician office labs (POLs) and outpatient clinics. Integrated design from sample preparation to results analysis and user friendly features are just as appealing to larger clinical labs to free up personnel. Menu expansion on integrated analyzers has been the predominant focus of competitors in molecular infectious disease diagnostics. Market share and client retention depend on the ability of one platform to perform all routine infectious disease tests. The Molecular diagnostics market is unrivaled among the IVD markets because of its superior technologies in terms of its performance and applicability. Microarray, next-generation sequencing and development-stage isothermal amplification methods represent promising contributions to the market space. For more information about this report visit http://www.researchandmarkets.com/research/sq7gtr/infectious


News Article | May 16, 2017
Site: globenewswire.com

DELRAY BEACH, Fla., May 16, 2017 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTC:PSID), a Life Sciences company focused on detection and diagnostics, announced today its financial results for the quarter ended March 31, 2017. The Company's Form 10-Q can be found in the Investor Relations section of its website. For the quarter ended March 31, 2017, revenues were $1.2 million, compared to $1.0 million for the prior sequential quarter, and $1.7 million for the quarter ended March 31, 2016. The decreased revenue from the first quarter of 2017 compared to the prior year quarter was driven by the delivery of two large projects in the Company’s Mobile Labs segment in early 2016. In early 2017 work progressed on several mobile labs, which will likely not be delivered until the second half of 2017. As individual projects are usually material, revenues can vary materially period to period based on the timing of such deliveries, and quarterly revenue as a result may not reflect results projected over an annual period. Cost of revenue was $0.8 million for the quarter ended March 31, 2017, compared to $0.7 million for the prior sequential quarter, and $1.1 million for quarter ended March 31, 2016. Gross margins increased to 34% for quarter ended March 31, 2017, compared to 32% for the prior sequential quarter and the quarter ended March 31, 2016. The decreased cost of revenue was primarily driven by the decrease in sales, while the improved margin resulted from improved mix of business. “During the first quarter of 2017, our businesses performed solidly, reporting an increase in revenue of 25% over the prior sequential quarter, with a focus on building a strong pipeline for the remainder of 2017,” stated William J. Caragol, Chairman and CEO of PositiveID. “While the timing of delivery of vehicles in our Mobile Labs segment can affect results from one quarter to another, we are confident in our business pipeline for the second half of the year, and looking at the big picture, we expect 2017 revenues will exceed 2016 revenues of $5.6 million.” PositiveID operates in three segments: Mobile Labs, comprised of its E-N-G Mobile Systems (“ENG”) subsidiary; Medical Devices, comprised of its Thermomedics subsidiary; and Molecular Diagnostics, consisting of its Firefly Dx prototype system for real-time pathogen detection. ENG designs and builds mobile laboratories, wireless support vehicles (cell-on-wheels and cell-on-light-trucks), radio frequency (“RF”) test platforms, broadcast news vehicles, and other technical vehicles. ​ENG has delivered more than 1,500 specialty vehicles to customers around the globe, including more than 400 mobile laboratories, 600 broadcast news vehicles, and more than 400 vehicles for cellular, RF, infrared, and other applications. Thermomedics markets the FDA-cleared Caregiver® thermometer, which is a clinical grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants, without contact. It delivers an oral-equivalent temperature directly from the forehead in one to two seconds. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs. PositiveID is developing the Firefly Dx prototype system to be a handheld, fully automated, lab quality, real-time device able to detect pathogens at the point of need, faster and less expensively than existing devices. Firefly's applications include point-of-need, lab-quality, detection of pathogenic organisms; agricultural and food screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction. About PositiveID Corporation PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn. Statements about PositiveID's future expectations, including the likelihood that several mobile labs will likely not be delivered until the second half of 2017; the likelihood that quarterly revenue may not reflect results projected over an annual period; the likelihood that the Company expects 2017 revenues will exceed 2016 revenues of $5.6 million; the likelihood that Firefly's applications include point-of-need, lab-quality, detection of pathogenic organisms, agricultural and food screening in both domestic sectors and developing countries, and detection of biological agents associated with weapons of mass destruction; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the specialty vehicle market; the Company’s ability to attract new customers and retain existing customers; the Company’s ability to target the professional healthcare market; the Company’s ability to raise capital; the Company’s ability complete the testing and development of Firefly Dx; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 31, 2017, and 10-Qs filed on May 15, 2017, November 18, 2016, and August 12, 2016, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.


Receive press releases from iHealthcareAnalyst, Inc.: By Email Global Biotechnology Market Research Reports, Competitive Analytics, Trends and Forecast 2017-2021 by iHealthcareAnalyst, Inc. Biotechnology Market reports by iHealthcareAnalyst, Inc. include Aptamers, Array Instruments, Bioinformatics, Biopreservation, Biosensors, Cancer Genome Sequencing, Cell Culture, Cell Culture Media, Sera, Reagents, Cell Culture Protein Surface Coatings, Cell Separation Technologies, Cell Surface Markers, Computational Biology, E. coli Diagnostics Testing, Genome Engineering or Genome Editing, Human Insulin, Immunoassay Analyzers, etc. Maryland Heights, MO, May 19, 2017 --( The global biotechnology market report provides market size (Revenue USD Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021). The global market research reports are divided by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global reports also provide detailed market landscape (market drivers, restraints, opportunities), market attractiveness and profitability analysis as well as profiles of major competitors in the global market which includes company overview, financial snapshot, key products, technologies and services offered, and recent developments. Browse Global Biotechnology Reports, Competitive Analytics, Growth Trends and Forecast 2017-2021 by iHealthcareAnalyst, Inc. at https://www.ihealthcareanalyst.com/reports/biotechnology/ Table of Contents 1. Introduction 2. Executive Summary 2.1. Market Size Estimation (Revenue USD Million, 2014-2021) 2.2. Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021) 3. Research Methodology 4. Market Landscape 4.1. Market Dynamics 4.1.1. Drivers 4.1.2. Barriers 4.1.3. Opportunities 4.2. Market Share Analysis 4.2.1. Companies 4.2.2. Products 4.3. Market Trends Analysis 4.3.1. Key success factors 4.3.2. Market Growth Rate 4.4. Market Attractiveness Analysis 4.5. Market Profitability Analysis 4.5.1. Buyer power 4.5.2. Supplier power 4.5.3. Barriers to entry 4.5.4. Threat of substitute products 4.5.5. Rivalry among firms in the industry 4.6. Distribution Channels 5. Market Segmentation 5.1. Product Type (cells, media, serum, vaccine, protein, instrument, etc.) 5.2. Source Type 5.3. Reagents and Consumables Type 5.4. Diagnostic Test 5.5. Indication Type 5.6. Technology 5.7. Diagnostics, Therapeutic or Surgical Application 5.8. End User Groups 6. Geography (Region, Country) 6.1. North America (U.S., Canada) 6.2. Latin America (Brazil, Mexico, Rest of LA) 6.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU) 6.4. Asia Pacific (Japan, China, India, Rest of APAC) 6.5. Rest of the World 7. Company Profiles 7.1. Company Overview 7.2. Financial Snapshot (FY 2014-2016) 7.3. Product Portfolio 7.4. Business Strategies 7.5. Recent Developments 8. Recommendations 9. References To request Table of Contents and Sample Pages of these reports visit: https://www.ihealthcareanalyst.com/reports/biotechnology/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, May 19, 2017 --( PR.com )-- The published titles of Biotechnology Market reports by iHealthcareAnalyst, Inc. include Aptamers, Array Instruments, Bioinformatics, Biopreservation, Biosensors, Cancer Genome Sequencing, Cell Culture, Cell Culture Media, Sera, Reagents, Cell Culture Protein Surface Coatings, Cell Separation Technologies, Cell Surface Markers, Computational Biology, E. coli Diagnostics Testing, Genome Engineering or Genome Editing, Human Insulin, Immunoassay Analyzers, Immunoprotein Diagnostic Testing, In Vitro Colorectal Cancer Testing, In Vitro Diagnostics, Life Science Reagents, Medical Cameras, Medical Microscopes, Meningococcal Vaccines, Metabolomics, Microbiology Cultures, Molecular Cytogenetics, Molecular Diagnostics, Monoclonal Antibody Therapeutics, Multiplexed Diagnostics, Next-Generation Sequencing, Non-alcoholic Steatohepatitis Biomarkers, Orthobiologics, Platelet Rich Plasma, Polymerase Chain Reaction, Prenatal and Newborn Genetic Testing, Protein Engineering, Regenerative Medicines, Separation Systems for Commercial Biotechnology, Single Cell Analysis, Single Nucleotide Polymorphism Genotyping, Sperm Bank, Stem Cells, Tissue Engineered Skin Substitutes, Transcriptomics Technologies, and Transfection Technologies.The global biotechnology market report provides market size (Revenue USD Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021). The global market research reports are divided by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global reports also provide detailed market landscape (market drivers, restraints, opportunities), market attractiveness and profitability analysis as well as profiles of major competitors in the global market which includes company overview, financial snapshot, key products, technologies and services offered, and recent developments.Browse Global Biotechnology Reports, Competitive Analytics, Growth Trends and Forecast 2017-2021 by iHealthcareAnalyst, Inc. at https://www.ihealthcareanalyst.com/reports/biotechnology/Table of Contents1. Introduction2. Executive Summary2.1. Market Size Estimation (Revenue USD Million, 2014-2021)2.2. Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)3. Research Methodology4. Market Landscape4.1. Market Dynamics4.1.1. Drivers4.1.2. Barriers4.1.3. Opportunities4.2. Market Share Analysis4.2.1. Companies4.2.2. Products4.3. Market Trends Analysis4.3.1. Key success factors4.3.2. Market Growth Rate4.4. Market Attractiveness Analysis4.5. Market Profitability Analysis4.5.1. Buyer power4.5.2. Supplier power4.5.3. Barriers to entry4.5.4. Threat of substitute products4.5.5. Rivalry among firms in the industry4.6. Distribution Channels5. Market Segmentation5.1. Product Type (cells, media, serum, vaccine, protein, instrument, etc.)5.2. Source Type5.3. Reagents and Consumables Type5.4. Diagnostic Test5.5. Indication Type5.6. Technology5.7. Diagnostics, Therapeutic or Surgical Application5.8. End User Groups6. Geography (Region, Country)6.1. North America (U.S., Canada)6.2. Latin America (Brazil, Mexico, Rest of LA)6.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)6.4. Asia Pacific (Japan, China, India, Rest of APAC)6.5. Rest of the World7. Company Profiles7.1. Company Overview7.2. Financial Snapshot (FY 2014-2016)7.3. Product Portfolio7.4. Business Strategies7.5. Recent Developments8. Recommendations9. ReferencesTo request Table of Contents and Sample Pages of these reports visit:https://www.ihealthcareanalyst.com/reports/biotechnology/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc.


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Top Technologies in Health and Wellness, 2017" report to their offering. This strategic research service, Health & Wellness Top 10 Technologies, depicts the current landscape and the new trends in a series of developments associated with innovations in Precision Oncology, Biobetters,Human Microbiomics, Immune Engineering, Cancer/Tumor Profiling, Cellular Therapeutics, Tissue Engineering, Molecular Diagnostics, Gene Editing and Predictive Biomarkers. Techvision's professionals have monitored, gathered, and analyzed numerous emerging and disruptive technologies selecting this top 10 technologies, by contacting an extensive network of innovators, technology developers, financial institutions, technologists and researchers, among other players in the ecosystem, with the aim to provide your company or institution with a notable intelligence work that can help you build and implement strong growth strategies by leverage disruptive technologies and emerging innovations. For more information about this report visit http://www.researchandmarkets.com/research/jfs2vp/top_technologies


News Article | May 23, 2017
Site: www.prnewswire.com

Molecular HLA typing methods allow more precise matching between donor and recipient and is especially critical to bone marrow or HSCT transplant outcomes. Allogenic HSCT transplantation is a relatively high growth procedure area compared to solid organ transplantation and is a leading area of application for molecular HLA typing. Polymorphism in the human major histocompability complex (MHC) or HLA system is exceedingly complex for serological methods and is best captured by directly assaying genetic sequence. The molecular HLA typing market is provided for various regions, and forecasts are made to 2021. In addition the report discusses trends affecting the molecular transplant matching market.  Successful solid organ and hematopoietic stem cell (HSCT) or bone marrow transplants require histocompatibility between the recipient and donor. Autologous transplantation using hematopoietic cells from the same patient (donor and recipient) is increasingly common and eliminates the need to screen for histocompatibility. However, solid organ transplants and HSCT allografts from another donor requires histocompatibility confirmed by human leukocyte antigen (HLA) testing outside of genetically identical twins. Proteins encoded by HLA system genes function as unique cell surface markers that regulate immune system recognition of foreign cells such as pathogens and tumor cells. Incompatibility between donor and recipient HLA systems or between donor tissue and recipient antibodies can result in severe complications such as transplant rejection. Testing of donor and recipient HLA systems is essential in cases of allograft between unrelated and even siblings. The most common forms of HLA typing are serological testing of HLA antigens and antibodies and detection of HLA alleles using a variety of molecular diagnostic techniques. Next-generation sequencing (NGS) is expected to develop into a leading option for the determination of HLA alleles. Key Topics Covered: 1: Executive Summary 2: Transplant Matching And Molecular Technology 3: Molecular Transplant Diagnostics Market And Market Share Analysis 4: Company Profiles - CareDx - Sequencing - Molecular HLA Typing - Illumina - Sequencing - Translational Research - Clinical Assay Development - Industry Lab-Developed Tests - Arrays - Immucor - Transfusion Diagnostics - Transplant Diagnostics - Immucor Dx Laboratory Service - Roche Diagnostics - Molecular Diagnostics - Thermo Fisher Scientific - Transplant Diagnostics - qPCR - Sequencing For more information about this report visit http://www.researchandmarkets.com/research/5zxkck/transplant Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/transplant-matching-molecular-diagnostics-market-2017-2021---research-and-markets-300462450.html

Loading Molecular Diagnostics collaborators
Loading Molecular Diagnostics collaborators